USA –
BOSTON, MA, Nereid Therapeutics has launched with a $50 million Series A funding commitment from ATP.
Apple Tree Partners (ATP) announced the launch of Nereid Therapeutics, a company dedicated to discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates. Nereid commences operations with a $50 million Series A funding commitment from ATP.
ATP created Nereid with Clifford P. Brangwynne, Ph.D., professor in the Department of Chemical and Biological Engineering at Princeton University.
Nereid Therapeutics is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and the resulting biomolecular condensates. Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases.
Nereid Therapeutics
245 Main St., FLOOR 12 – Cambridge, MA 02142
